Your browser doesn't support javascript.
loading
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers.
Forsberg, Lars; Spelman, Tim; Klyve, Pernilla; Manouchehrinia, Ali; Ramanujam, Ryan; Mouresan, Elena; Drahota, Jiri; Horakova, Dana; Joensen, Hanna; Pontieri, Luigi; Magyari, Melinda; Ellenberger, David; Stahmann, Alexander; Rodgers, Jeff; Witts, James; Middleton, Rod; Nicholas, Richard; Bezlyak, Vladimir; Adlard, Nicholas; Hach, Thomas; Lines, Carol; Vukusic, Sandra; Soilu-Hänninen, Merja; van der Walt, Anneke; Butzkueven, Helmut; Iaffaldano, Pietro; Trojano, Maria; Glaser, Anna; Hillert, Jan.
Afiliación
  • Forsberg L; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Spelman T; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Klyve P; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Manouchehrinia A; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Ramanujam R; Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Mouresan E; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Drahota J; Department of Mathematics, Royal Institute of Technology, Stockholm, Sweden.
  • Horakova D; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Joensen H; Czech National Multiple Sclerosis ReMuS, IMPULS Endowment Fund, Prague, Czech Republic.
  • Pontieri L; First Faculty of Medicine and General University Hospital, Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, Prague, Czech Republic.
  • Magyari M; First Faculty of Medicine and General University Hospital, Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, Prague, Czech Republic.
  • Ellenberger D; The Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Copenhagen, Denmark.
  • Stahmann A; The Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Copenhagen, Denmark.
  • Rodgers J; The Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Copenhagen, Denmark.
  • Witts J; Danish Multiple Sclerosis Center, Copenhagen University Hospital, Copenhagen, Denmark.
  • Middleton R; MS Forschungs- und Projektentwicklungs-gGmbH, Hannover, Germany.
  • Nicholas R; MS Forschungs- und Projektentwicklungs-gGmbH, Hannover, Germany.
  • Bezlyak V; Swansea University Medical School, Swansea, UK.
  • Adlard N; Swansea University Medical School, Swansea, UK.
  • Hach T; Swansea University Medical School, Swansea, UK.
  • Lines C; Swansea University Medical School, Swansea, UK.
  • Vukusic S; Department of Cellular and Molecular Neuroscience, Imperial College London, London, UK.
  • Soilu-Hänninen M; Novartis Pharma AG, Basel, Switzerland.
  • van der Walt A; Novartis Pharma AG, Basel, Switzerland.
  • Butzkueven H; Novartis Pharma AG, Basel, Switzerland.
  • Iaffaldano P; Novartis Pharma AG, Basel, Switzerland.
  • Trojano M; Hôpital Neurologique, Service de Neurologie A, the European Database for Multiple Sclerosis (EDMUS), Coordinating Center and INSERM U 433, Lyon, France.
  • Glaser A; Division of Clinical Neurosciences, University Hospital and University of Turku, Turku, Finland.
  • Hillert J; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia.
Mult Scler J Exp Transl Clin ; 9(1): 20552173231153557, 2023.
Article en En | MEDLINE | ID: mdl-36816812
Background: To assign a course of secondary progressive multiple sclerosis (MS) (SPMS) may be difficult and the proportion of persons with SPMS varies between reports. An objective method for disease course classification may give a better estimation of the relative proportions of relapsing-remitting MS (RRMS) and SPMS and may identify situations where SPMS is under reported. Materials and methods: Data were obtained for 61,900 MS patients from MS registries in the Czech Republic, Denmark, Germany, Sweden, and the United Kingdom (UK), including date of birth, sex, SP conversion year, visits with an Expanded Disability Status Scale (EDSS) score, MS onset and diagnosis date, relapses, and disease-modifying treatment (DMT) use. We included RRMS or SPMS patients with at least one visit between January 2017 and December 2019 if ≥ 18 years of age. We applied three objective methods: A set of SPMS clinical trial inclusion criteria ("EXPAND criteria") modified for a real-world evidence setting, a modified version of the MSBase algorithm, and a decision tree-based algorithm recently published. Results: The clinically assigned proportion of SPMS varied from 8.7% (Czechia) to 34.3% (UK). Objective classifiers estimated the proportion of SPMS from 15.1% (Germany by the EXPAND criteria) to 58.0% (UK by the decision tree method). Due to different requirements of number of EDSS scores, classifiers varied in the proportion they were able to classify; from 18% (UK by the MSBase algorithm) to 100% (the decision tree algorithm for all registries). Objectively classified SPMS patients were older, converted to SPMS later, had higher EDSS at index date and higher EDSS at conversion. More objectively classified SPMS were on DMTs compared to the clinically assigned. Conclusion: SPMS appears to be systematically underdiagnosed in MS registries. Reclassified patients were more commonly on DMTs.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Mult Scler J Exp Transl Clin Año: 2023 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Mult Scler J Exp Transl Clin Año: 2023 Tipo del documento: Article País de afiliación: Suecia